Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Drug transporters are increasingly recognized to be important to drug disposition and
response. P‐glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of …

Imatinib is a tyrosine kinase inhibitor that is effective in the treatment of chronic myeloid
leukemia (CML). Not all patients achieve cytogenetic response. Some patients even lose the …

Abstract Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used
in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors …

Abstract Purpose: On June 28, 2006, the US Food and Drug Administration approved
dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine …

Some chronic myeloid leukemia (CML) patients do not respond to imatinib, whereas others
lose an initial response. To identify potential imatinib failures, we investigated the …

Imatinib mesylate is approved for the treatment of chronic myeloid leukemia (CML) and
advanced gastrointestinal stromal tumors (GIST). Unfortunately, in the course of treatment …

Imatinib mesylate is a selective tyrosine kinase inhibitor that is successfully used in the
treatment of Philadelphia-positive chronic and acute leukaemia's, and gastrointestinal …

Nine proteins of the ABC superfamily (P-glycoprotein, 7 MRPs and BCRP) are involved in
multidrug transport. Being localised at the surface of endothelial or epithelial cells, they …

Purpose: The organic cation transporter OCT-1 mediates active transport of imatinib. We
recently showed that low OCT-1 activity is a major contributor to suboptimal response in …